Supplemental materials to

Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine

Supplementary Methods		
Supplementary Methods 1 (Suppl. S1)	Risk-set sampling of unvaccinated study individuals	
	Codes used to identify cohort inclusion and exclusion	
Supplementary Methods 2 (Suppl. S2)		
Supplementary Methods 3 (Suppl. S3)	Codes of pre-exposure covariates used for confounding adjustment via propensity score matching	
Supplementary Methods 4 (Suppl. S4)	Vaccine under-reporting and correction	
Supplementary Methods 5 (Suppl. S5)	Month-by-month effectiveness analyses	
Supplementary Figures		
Figure S1	Study design diagram	
Figure S2	Plot of Schoenfeld residuals for any observed COVID-19 primary analysis.	
Figure S3	Diagrams for methods used to calculate month-specific effectiveness estimates.	
<u>Supplementary Tables</u> (see attached excel document f	or supplementary tables)	
Table S0	Study population counts and attrition	
Table S1	Characteristics of Ad26.COV2.S vaccinated and matched unvaccinated individuals in national cohort, by age and immunocompromised subgroups.	
Table S2	Characteristics of Ad26.COV2.S vaccinated and matched unvaccinated individuals in high-Delta- incidence States, overall and by age and immunocompromised subgroups.	
Table S3	Incidence and vaccine effectiveness for COVID-19 and COVID-19-related hospitalizations - high-Delta- incidence States, overall and by age and immunocompromised subgroups.	
Table S4	Incidence and vaccine effectiveness for COVID-19 and COVID-19-related hospitalizations - Regional subgroups.	

Supplement Contents

Table S5	Correction of the VE regarding observed COVID-19 with varying assumptions about the level of under-recording in claims data.
Table S6	Correction of the VE regarding COVID-19-related hospitalizations with varying assumptions about the level of under-recording in claims data.
Table S7	Incidence and vaccine effectiveness for COVID-19 and COVID-19-related hospitalizations defined by laboratory NAAT test results only.
Table S8	Incidence and vaccine effectiveness for COVID-19 and COVID-19-related hospitalizations among cohort meeting data extraction criteria before cohort entry.
Table S9	Characteristics of Ad26.COV2.S vaccinated and risk-set sample matched unvaccinated individuals in national cohort prior to propensity score matching.

Supplementary Methods 1 (Suppl. S1): Risk-set sampling of unvaccinated study individuals

A two-step process was used to identify a referent group of non-vaccinated individuals available for follow-up on the same date and geography as all identified exposed individuals. This two-step process first included risk-set sampling via exact matching exposed (vaccinated) individuals with up to ten non-vaccinated (referent) individuals on: time (calendar date), age (within age categories of 18-24; 25-29; 30-34; 35-39; 40-44; 45-49; 50-54; 55-59; 60-64; 65-69; 70-74; 75-79; 80-84; 85+), sex, geography (based on 3-digit ZIP codes), and Gagne Combined Comorbidity Index based on 365 day baseline period (categories: 0-1, 2-3, 4-5, 6+).

From these risk-set sampled patients, PS matching as described in the manuscript was performed.

Variable name	RWD Definition
Administration of the Janssen Ad26.COV2.S vaccine (inclusion)	Any medical claim, pharmacy claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following CPT or NDC codes recorded: CPT codes: 91303, 0031A NDC codes: 59676-580-05, 59676-0580-05, 59676-0580-15, 59676-580-15 OR Any retail pharmacy claim for a COVID-19 vaccine with the following manufacturer name: "JANSSEN", "JANSSEN (DIVISION OF JOHNSON AND JOHNSON)", "JOHNSON AND JOHNSON", "JSN" and CVX code is 212
	Note: CVX codes are codes that indicate the product used in a vaccination and are maintained

Supplementary Methods 2 (Suppl. S2): Codes used to identify cohort inclusion and exclusion variables

	by the CDC's National Center of Immunization and Respiratory Diseases.
Evidence of prior observed COVID-19 (exclusion)	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes: U07.1 Z20.822 Z86.16 J12.82 OR Record of any positive result from a COVID-19 diagnostic or antibody laboratory test.
Administration of any COVID-19 vaccine (exclusion)	Administration of the Janssen Ad26.COV2.S vaccine OR Administration of an mRNA vaccine (Pfizer or Moderna): {Any medical claim, pharmacy claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following CPT or NDC codes recorded: CPT codes: 0001A, 0002A, 0012A, 0011A, 91300, 91301 NDC codes: 80777-0273-10, 59267-1000-01, 59267-1000-1, 80777-273-10, 59267-1000-2, 59267-1000-02, 59267-1000-03, 80777-0273-15, 80777-0273-98, 80777-273-15, 80777-273-99, 80777-0273-99 OR Any retail pharmacy claim for a COVID-19 vaccine with the following manufacturer name: "MOD", "MODERNA", "MODERNA US, INC", "MODERNA US, INC.", "PFIZER", "PFIZER, INC", "PFR" and CVX code is 207 or 208 Note: CVX codes are codes that indicate the product used in a vaccination and are maintained by the CDC's National Center of Immunization and Respiratory Diseases.

Variable name	RWD Definition
Chronic obstructive pulmonary disease (COPD)	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : 127.8 127.9 J40 J41 J42 J43 J44 J45 J46 J47 J60 J61 J62 J63 J64 J65 J66 J67 J68.4 J70.1 J70.3
Pulmonary fibrosis	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ² : J61 J62.0 J62.8 J63.0 J63.1 J63.2 J63.3 J63.4 J63.5 J63.6 J64 J65 J66.0 J66.1 J66.2

Supplementary Methods 3 (Suppl. S3): Codes of pre-exposure covariates used for confounding adjustment via propensity score matching

	J66.8 J70.1 J84.01 J84.02 J84.03 J84.09 J84.10 J84.110 J84.112 J84.113 J84.114 J84.115 J84.116 J84.117 J84.170 J84.178 J84.2 J84.841 J84.842 J84.843 J84.843 J84.848 J84.89 J84.9
HIV infection	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ³ : B20 B97.35 R75 Z21
Immunocompromised status (as used for subgroups)	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes: B20, D80-84, D89.8-9, Z21, Z94 Reference and evidence for association: Williamson E, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-443. https://doi.org/10.1038/s41586-020-2521-4.

	Codes obtained from: I-MOVE-COVID-19 Network. "COVID-19 vaccine effectiveness at primary care level in Europe: generic protocol". ENCePP EU-PAS Register. Accessed 26 May 2021.
Immunocompromised state from blood transplant	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM procedure codes: 30230AZ 30230G1-G4 30230X1-X4 30233Y1-Y4 30233AZ 30233G1-G4 30233X1-S4 30240AZ 30240G1-G4 30240X1-X4 30240Y1-Y4 30243AZ 30243G1-G4 30243X1-X4 30243Y1-Y4 30250G1 30250X1 30250Y1 30250Y1 30253X1 30260Y1 30260X1 30260X1 30260X1 30260X1 30263X1 30263Y1 ICD-10 diagnosis codes: D84.81 D84.9 D81.1 T86.00 T86.09 Z48.290 Z94.81

Immunocompromised state from organ transplant	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following DRG procedure code ⁴ : DRG procedure codes kidney: 302 heart: 103 lung: 495 Liver: 480 ICD-10 codes: D84.821 D84.9 Z48.21 Z48.22 Z48.23 Z48.24 Z48.288 Z94.0 Z94.1 Z94.2 Z94.3 Z94.4 Z94.82 Z94.83 T86.10 T86.19 T86.20 T86.298 T86.30 T86.39 T86.40 T86.49 T86.818 T86.819 T86.855 T86.859 T86.898
Liver disease	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : B15.9 B16.0 B16.1 B16.2 B16.9 B17.0

B17 10
D17.10
B17.11
D17 0
D17.2
B17.8
D170
B1/.9
B18
D10 0
B19.0
B19.10
D10.11
B19.11
B19.20
B19.20
B19.21
B19.9
B66.1
R66 3
D00.5
185
186.4
198.2
K70
K71.0
K711
K71.10
V71 11
K/1.11
K71.2
V71 2
K/1.5
K71.4
V715
K/1.3
K71.50
V71 51
K/1.51
K716
K/1./
K718
K/1.9
K72
K/3
K74
K/5.0
K75 1
K75.2
K75 3
К/Э.4
K75 81
K75.89
K75 0
K76.0
K761
K/0.1
K76.2
K763
N /0.3
K76.4
V765
$\Lambda/0.J$
K76.6

	K76.7 K76.8 K76.81 K76.9 K77 Q44.6 Z94.4
Malignancies (excluding non-melanoma skin cancer)	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 C33 C34 C37 C38 C39 C40

C41
C41
C43
045
C45
C46
047
C47
C48
C49
C50
0.50
C51
C52
0.52
C53
C54
0.04
C55
056
0.50
C57
C59
CJ0
C60
C(1
C01
C62
0(2
C63
C64
C65
C66
C67
C68
008
C69
C70
C70
C71
C72
C12
C73
C74
C/4
C75
C76
C/0
C81
C92
62
C83
<u>C</u> Q4
C04
C85
C00
688
C90
C01
(9)
C92
C93
C94
C95
C96
C97

Moderate-to- severe asthma	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ⁵ : J45.40 J45.41 J45.42 J45.50 J45.51 J45.51 J45.52
Cerebrovascular disease	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : G45 G46 H34.0 I60 I61 I62 I63 I64 I65 I66 I67 I68 I69
Chronic kidney disease	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : I12.0 13.1 N03.2 N03.3 N03.4 N03.5 N03.6 N03.7 N05.2 N05.3 N05.4 N05.5 N05.6 N05.7 N18 N19 N25.0

	Z49.0 Z49.1 Z49.2 Z94.0 Z99.2
Hypertension	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : 110 111 112 113 115 116 127.0 127.1 127.20 127.21 127.22 127.23 127.24 127.29 167.4 187.301 187.302 187.303 187.309 187.311 187.312 187.313 187.319 187.31 187.32 187.32 187.33 187.32 187.33 187.339 187.331 187.32 187.332 187.332 187.333 187.339 187.331 187.332 187.333 187.339 187.331 187.332 187.333 187.339 187.331 187.332 187.333 187.339 187.331 187.332 187.333 187.339 187.331 187.332 187.333 187.339 187.339 187.399 197.3 K76.6 R03.0

	G93.2
Serious heart conditions	G95.2 Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ^{1.6} : 109.9 111.0 113.0 113.2 125.5 142.0 142.5-142.9 143 150 P29.0 120 121 122 123 124 125 105 106 107 108 120.0 120.1 120.8 120.9 123.7 124.0 124.1 124.8 124.9
	I25.10 I25.110 I25.111 I25.118 I25.119 I25.2 I25.5 I26.01 I26.02 I26.09 I26.90
	I26.92 I26.99 I27.0

	$\begin{array}{c} 127.1 \\ 127.2 \\ 127.81 \\ 127.82 \\ 414.10 \\ 414.11 \\ 414.12 \\ 414.19 \\ 429.1 \\ 429.2 \\ 429.3 \\ 429.5 \\ 429.5 \\ 429.6 \\ 429.71 \\ 429.79 \\ 429.81 \end{array}$
Obesity	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ^{1,7} : Z68.30 Z68.31 Z68.32 Z68.33 Z68.34 Z68.35 Z68.36 Z68.37 Z68.38 Z68.39 Z68.41 Z68.42 Z68.43 Z68.43 Z68.44 Z68.45 Z68.51 Z68.52 Z68.53 Z68.54 Z98.0 Z98.84 E66
Sickle Cell Disease	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes: D57

Thalassemia	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes: D56
Type 1 diabetes mellitus	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : E10
Type 2 diabetes mellitus	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM codes ¹ : E11
Neurologic conditions	Any medical claim, inpatient hospital encounter, or outpatient hospital encounter with one of the following ICD-10-CM $codes^{3.8}$: F01 F00 G00.0 G00.1 G00.2 G00.3 G00.8 G00.9 G01-G14 G20-G26 G30-G32 G31 (exclude G31.2) G35-37 G40 G43-G47 G50-G65 G70-G73 G80-G83 G89-99 G45.8 G45.9 I60-I63 I65-I69 F03 F04 R29 R41 S06 Z86.73 Z87.820 F02.81

	F05 F06.0 F06.8 F10.27 F19.97
Number of pharmacy claims	The count of events occurring in the "Pharmacy Claims" table over the baseline period
Number of medical claims	The count of events occurring in the "Medical Claims" table over the baseline period
Recent medical claims	True if any event begins in the "Medical Claims" table in the 60 days prior to index
Recent pharmacy claim	True if any event begins in the "Pharmacy Claims" table in the 60 days prior to index
Age	Age defined as continuous numeric variable for propensity score modeling.
Sex	Male/Female
Comorbidity score (exact)	Gagne Combined Comorbidity Index
Calendar month of index date	The calendar month in which the index date occurs may be one of the following: 2021-03, 2021-04, 2021-05, 2021-06, 2021-07
State	Classified based on U.S. state, D.C., or miscellaneous U.S. territory recorded on index date.

Supplementary Methods 4 (Suppl. S4): Vaccine under-recording and correction

To assess under-recording of vaccination, we compared CDC-reported vaccination numbers to the number of observed COVID-19 vaccinations within the national open claims data used for this study. The CDC reported nationwide 162 million fully vaccinated people out of 283.7 million people 12 years and older in the US (~57%) as of July 22, 2021. Within the HealthVerity dataset used for the current study (data through July 2021), we observed 54 million individuals with any COVID-19 vaccination out of 161 million people included in the dataset (~34%). The under-recording of COVID-19 vaccinations in the national claims data used for this study can thus be approximated by $57\% - 34\% \approx 23$ percentage points, which equates to ~59% sensitivity of exposure assessment.

Such reduced sensitivity of exposure assessment leads to an underestimation of the true effectiveness, as our unvaccinated comparator population likely includes patients who were vaccinated at mass vaccination sites, pharmacies, and other organizations without submitting claims to insurance companies and thus our study data source.⁹ In order to be conservative, our primary analysis assumed an under-reporting of 40% (sensitivity of 60%) for all bias-corrected effect estimates.

Assuming a 40% estimated proportion of vaccination under-reporting in claims data, we used standard algebraic methods to correct relative risk estimates assuming 100% specificity of vaccination recording.¹⁰ Observed and corrected relative risks and 95% confidence intervals were calculated by specifying a 61-day fixed follow-up period that began 14 days post-index among vaccinated and 1:1 PS matched unvaccinated patients. From this fixed follow-up analysis, specific bias correction factors were derived for each outcome¹⁰ and all subgroups of interest, and then applied to hazard ratio and rate ratio-based effectiveness estimates from the primary analysis.

Table S5. Correction of the VE regarding ob	served COVID-19 outcomes v	with varying assumptions about th	e level of
under-recording in claims data			

Assumed under-recording of	0%	10%	20%	30%	40%*	50%	60%	70%
COVID-19 vaccination status								
in national claims data								
Sensitivity of COVID-19	100%	90%	80%	70%	60%	50%	40%	30%
vaccine exposure								
Uncorrected (observed) HR	0.31	0.31	0.31	0.31	0.31	0.31	0.31	0.31
(95% CI)	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,
	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)
Uncorrected (observed)	69%	69%	69%	69%	69%	69%	69%	69%
Effectiveness (95% CI)	(67%,	(67%,	(67%,	(67%,	(67%,	(67%,	(67%,	(67%,
	71%)	71%)	71%)	71%)	71%)	71%)	71%)	71%)
Corrected HR (95% CI)	0.31	0.29	0.27	0.24	0.21	0.19	0.16	0.12
	(0.29,	(0.27,	(0.25,	(0.23,	(0.20,	(0.17,	(0.15,	(0.11,
	0.33)	0.31)	0.28)	0.26)	0.23)	0.20)	0.17)	0.13)
Corrected Effectiveness (95%	69%	71%	73%	76%	79%	81%	84%	88%
CI)	(67%,	(69%,	(72%,	(74%,	(77%,	(80%,	(83%,	(87%,
	71%)	73%)	75%)	77%)	80%)	83%)	85%)	89%)

* Primary Analysis

Table S6. Correction of the VE regarding COVID-19-related hospitalizations with varying assumptions about the level of under-recording in claims data

Assumed under-recording of COVID-19 vaccination status	0%	10%	20%	30%	40%*	50%	60%	70%
in national claims data	1000/	000/	900/	700/	(00/	500/	400/	200/
Sensitivity of COVID-19	100%	90%	80%	/0%	60%	50%	40%	30%
	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.21
Uncorrected (observed) HR	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51
(95% CI)	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,	(0.29,
	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)	0.33)
Uncorrected (observed)	73%	73%	73%	73%	73%	73%	73%	73%
Effectiveness (95% CI)	(69%,	(69%,	(69%,	(69%,	(69%,	(69%,	(69%,	(69%,
	76%)	76%)	76%)	76%)	76%)	76%)	76%)	76%)
Corrected HR (95% CI)	0.27	0.25	0.23	0.21	0.19	0.16	0.13	0.10
	(0.24,	(0.22,	(0.20,	(0.19,	(0.16,	(0.14,	(0.12,	(0.09,
	0.31)	0.29)	0.26)	0.24)	0.21)	0.18)	0.15)	0.12)
Corrected Effectiveness (95%	73%	75%	77%	79%	81%	84%	87%	90%
CI)	(69%,	(71%,	(74%,	(76%,	(79%,	(82%,	(85%,	(88%,
	76%)	78%)	80%)	81%)	84%)	86%)	88%)	91%)

* Primary Analysis

Supplementary Methods 5 (Suppl. S5): Month-by-month effectiveness analyses

To assess vaccine effectiveness over calendar time, we examined incident rate ratios separately for each calendar month within the overall national cohort and high-Delta-incidence States (**Fig 3**). **Table 2** also shows effectiveness estimates for the combined period June to July 2021 for high-Delta-incidence states, given the emergence of the Delta variant during this 2 month period.

Only outcome events and eligible person-time occurring within each person's follow-up period for main effectiveness analyses (March 2021 to July 2021) were included in month-level incident rate ratio calculations. Persons could contribute eligible person-time for multiple months, and/or for partial months, but were excluded from monthly person-time totals if censored from analysis. **Figure S3** shows how month-by-month person-time denominators were derived for 2 hypothetical study participants.

Using this approach, monthly incident rates were calculated as the (number of outcome events beginning in each calendar month) / (the total number of person-years within each month for which persons were eligible for outcomes). Incident rate ratios were calculated for each month as the ratio of outcome rates in exposed vs unexposed patients, and effectiveness estimates were then corrected for vaccine under-recording in claims data using the methods described in **Suppl. S4**.



Figure S1. Study design diagram

1 - Number of pharmacy/medical claims and comorbidities

2 - Age, sex and state

3 - Day 14 through observed endpoint or censoring



Figure S2. Plot of Schoenfeld residuals for any observed COVID-19 primary analysis



Figure S3. Diagrams for methods used to calculate month-specific effectiveness estimates

References in supplementary materials

1. Quan H, Sundararajan V, Halfon P, et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data: Medical Care 2005;43(11):1130–9.

2. Jones N, Schneider G, Kachroo S, Rotella P, Avetisyan R, Reynolds MW. A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data: DETECTION OF PULMONARY FIBROSIS IN CLAIMS. Pharmacoepidemiol Drug Saf 2012;21:256–60.

3. Fireman B, Toh S, Butler MG, et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent: ACTIVE SURVEILLANCE OF ACUTE MYOCARDIAL INFARCTION. Pharmacoepidemiol Drug Saf 2012;21:282–90.

4. Beckman KD. Coding Common Respiratory Problems in ICD-10. FPM 2014;21(6):17-22.

5. Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. Cancer Epidemiol Biomarkers Prev 2010;19(5):1229–37.

6. Lindgren M, Robertson J, Adiels M, et al. Elevated resting heart rate in adolescent men and risk of heart failure and cardiomyopathy. ESC Heart Failure 2020;7(3):1178–85.

7. Caplan EO, Kamble PS, Harvey RA, et al. Positive predictive value between medical-chart body-massindex category and obesity versus codes in a claims-data warehouse. Current Medical Research and Opinion 2018;34(1):117–21.

8. Fujiyoshi A, Jacobs DR, Alonso A, Luchsinger JA, Rapp SR, Duprez DA. Validity of Death Certificate and Hospital Discharge ICD Codes for Dementia Diagnosis: The Multi-Ethnic Study of Atherosclerosis. Alzheimer Disease & Associated Disorders 2017;31(2):168–72.

9. Rothman KJ, Lash TL, VanderWeele TJ, Haneuse S. Modern epidemiology. Fourth edition. Philadelphia: Wolters Kluwer; 2021.

10. Lash TL, Fox MP, Fink AK. Applying Quantitative Bias Analysis to Epidemiologic Data. 1st ed. New York: Springer; 2009.